Tag: website

MAJURO, Marshall Islands, June 18, 2026 (GLOBE NEWSWIRE) --

SeerDEX has launched a Solana-based platform offering binary options and prediction markets, paired with $SEERX, a token funded in part by protocol-level buybacks.

REYKJAVIK, ICELAND (June 18, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing on June 17, 2026 of its previously announced underwritten public offering (the “Offering”) of 26,066,667 of its ordinary shares at an offering price of $3.75 per share, which includes 3,400,000 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the Offering. All ordinary shares sold in the Offering were offered by Alvotech. Before deducting the underwriting discounts and commissions and offering expenses, the aggregate gross proceeds to the Company were approximately $98 million.

Realkredit Danmark will open 6 new mortgage-coverd bonds (SDRO’s).

The new mortgage-covered bonds will be admitted to trading on Nasdaq Copenhagen.

The new mortgage-covered bonds are covered by the "Base prospectus for mortgage-covered bonds and mortgage bonds issued by Realkredit Danmark A/S."

The base prospectus is available on Realkredit Danmark's website at www.rd.dk/Investor.

The final terms are hereby published.

Please contact Hella Gebhardt Rønnebæk on tel. +45 45 13 20 68 if you have any questions.

Attachment

MANCHESTER, United Kingdom and OSAKA, Japan, June 18, 2026 (GLOBE NEWSWIRE) -- F2G Ltd and Shionogi & Co., Ltd (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D) (“Shionogi”) today announced positive topline results from the global Phase 3 OASIS study (NCT05101187), comparing the investigational oral antifungal drug olorofim versus AmBisome® (liposomal amphotericin B for injection) followed by standard of care (SOC) in patients with invasive aspergillosis whose infection is either refractory to or unsuitable for azole therapy.

DUBAI, United Arab Emirates, June 18, 2026 (GLOBE NEWSWIRE) --

Pepeto just completed a major upgrade on its exchange in a week where every Ethereum price prediction moved higher, pushing the zero-cost trading engine closer to launch. The presale crossed $10.28 million, and the biggest entries came in while sentiment sat at its lowest point this year, exactly when smaller buyers step back and serious money steps forward. Three live products run, 170% staking APY locks holders in, and the Binance listing is expected before the market catches up.

BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (“ADSs”), each representing two ordinary shares of the Company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by Legend Biotech. The gross proceeds to Legend Biotech from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Legend Biotech, are expected to be approximately $226 million, excluding any proceeds from the exercise of the underwriters’ option to purchase additional ADSs. The offering is expected to close on June 23, 2026, subject to customary closing conditions.